This study involves receiving blinatumomab after high-dose melphalan and autologous stem cell transplant (ASCT) for multiple myeloma. The main purpose of this study is to:
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
There are no resources, links or videos to display for this clinical trial.